DK1385522T3 - Kombination indeholdende en signaltransduktionsinhibitor og et epothilonderivat - Google Patents

Kombination indeholdende en signaltransduktionsinhibitor og et epothilonderivat

Info

Publication number
DK1385522T3
DK1385522T3 DK02744903T DK02744903T DK1385522T3 DK 1385522 T3 DK1385522 T3 DK 1385522T3 DK 02744903 T DK02744903 T DK 02744903T DK 02744903 T DK02744903 T DK 02744903T DK 1385522 T3 DK1385522 T3 DK 1385522T3
Authority
DK
Denmark
Prior art keywords
signal transduction
combination containing
combination
transduction inhibitor
epothilone derivative
Prior art date
Application number
DK02744903T
Other languages
Danish (da)
English (en)
Inventor
Elisabeth Buchdunger
Carl-Henrik Heldin
Arne Oestman
Kristian Pietras
Terence O'reilly
John David Rothermel
Peter Traxler
Markus Wartmann
Ralf Brandt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1385522T3 publication Critical patent/DK1385522T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02744903T 2001-02-27 2002-02-26 Kombination indeholdende en signaltransduktionsinhibitor og et epothilonderivat DK1385522T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (1)

Publication Number Publication Date
DK1385522T3 true DK1385522T3 (da) 2009-10-12

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02744903T DK1385522T3 (da) 2001-02-27 2002-02-26 Kombination indeholdende en signaltransduktionsinhibitor og et epothilonderivat

Country Status (22)

Country Link
US (1) US7723339B2 (https=)
EP (1) EP1385522B1 (https=)
JP (1) JP4499359B2 (https=)
KR (1) KR100848197B1 (https=)
CN (1) CN1511036B (https=)
AT (1) ATE434438T1 (https=)
AU (1) AU2002308218B2 (https=)
BR (1) BR0207649A (https=)
CA (1) CA2439268C (https=)
CY (1) CY1109347T1 (https=)
DE (1) DE60232719D1 (https=)
DK (1) DK1385522T3 (https=)
ES (1) ES2326264T3 (https=)
IL (2) IL157466A0 (https=)
MX (1) MXPA03007729A (https=)
NO (1) NO325416B1 (https=)
NZ (1) NZ527764A (https=)
PL (1) PL207197B1 (https=)
PT (1) PT1385522E (https=)
RU (1) RU2313345C2 (https=)
SK (1) SK287489B6 (https=)
WO (1) WO2002067941A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
EP1441736A2 (en) * 2001-10-29 2004-08-04 Novartis AG Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
HK1044946A1 (zh) * 1999-02-11 2002-11-08 舍林股份公司 依泊昔酮衍生物、其製備方法及藥物用途
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
KR20040025900A (ko) 2004-03-26
JP2004527493A (ja) 2004-09-09
PT1385522E (pt) 2009-09-04
WO2002067941A8 (en) 2003-12-18
KR100848197B1 (ko) 2008-07-24
CA2439268C (en) 2010-01-19
NO325416B1 (no) 2008-04-21
CN1511036B (zh) 2010-05-05
RU2003127392A (ru) 2005-03-27
WO2002067941A2 (en) 2002-09-06
NO20033769L (no) 2003-08-25
SK287489B6 (sk) 2010-11-08
CN1511036A (zh) 2004-07-07
IL157466A0 (en) 2004-03-28
DE60232719D1 (de) 2009-08-06
CY1109347T1 (el) 2014-07-02
AU2002308218B2 (en) 2005-11-10
RU2313345C2 (ru) 2007-12-27
NO20033769D0 (no) 2003-08-25
JP4499359B2 (ja) 2010-07-07
ATE434438T1 (de) 2009-07-15
NZ527764A (en) 2006-01-27
HK1062266A1 (en) 2004-10-29
EP1385522A2 (en) 2004-02-04
IL157466A (en) 2012-04-30
MXPA03007729A (es) 2003-12-04
ES2326264T3 (es) 2009-10-06
WO2002067941A3 (en) 2003-11-20
US7723339B2 (en) 2010-05-25
EP1385522B1 (en) 2009-06-24
CA2439268A1 (en) 2002-09-06
SK10712003A3 (sk) 2004-02-03
BR0207649A (pt) 2004-03-09
US20040132754A1 (en) 2004-07-08
PL207197B1 (pl) 2010-11-30
PL363288A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
CY1109347T1 (el) Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης
PL371466A1 (en) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
BR0314112A (pt) Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
CY2022009I1 (el) Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
NO20033491D0 (no) Heterocykliske inhibitorer av ERK2 og anvendelser derav
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
NO20043902L (no) Kontrollert syntese av ziprasidon og sammensetninger derav
NO20034713L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)- benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og et kjemoterapeutiskmiddel
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE60207641D1 (de) Halbleiterspeicher, Informationsgerät und Verfahren zur Bestimmung von Speicherzugriffzeit des Halbleiterspeichers
DE10204822B8 (de) Eingabe-/Ausgabeleitungs-Abtastverstärker eines Halbleiterspeicherbauelementes
IL176070A0 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
NO20023956D0 (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
EP1434863A4 (en) IDENTIFICATION AND USE OF MAMMALIAN P21 INHIBITORS
ATE348615T1 (de) 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
HK1095273A (en) Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
DE60319211D1 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
ATE298333T1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon- (e)-o-methyloxim und seinen salzen
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf
HK1071316A (en) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer